Sinobiopharma Inc
Sinobiopharma is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products.
See more information about Sinobiopharma Inc
Sinobiopharma gains approval for the use of Gabexate Mesylate as pharmaceutical raw material
Sinobiopharma, Inc. (OTC: SNBP) has received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material from the Chinese State Food and Drug Administration ("SFDA").
Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis.
The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
The Company is now awaiting GMP certification to manufacture Gabexate mesylate.
Other Sinobiopharma Inc news
- Sinobiopharma signs distribution contracts for flagship product
2010-07-06 - Sinobiopharma appoints Chief Financial Officer and Director to the Board
2009-09-30 - Emissary starts coverage of Sinobiopharma with Buy target of $1.25
2009-09-22
